Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People’s Republic of China and internationally. More Details
Excellent balance sheet and good value.
Share Price & News
How has Essex Bio-Technology's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1061 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: 1061's weekly volatility (11%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 1061 underperformed the Hong Kong Biotechs industry which returned 63.8% over the past year.
Return vs Market: 1061 underperformed the Hong Kong Market which returned 29.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Essex Bio-Technology's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StIs Essex Bio-Technology (HKG:1061) A Risky Investment?
4 weeks ago | Simply Wall StIf You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today
1 month ago | Simply Wall StHow Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?
Is Essex Bio-Technology undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1061 (HK$5.38) is trading below our estimate of fair value (HK$34.86)
Significantly Below Fair Value: 1061 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1061 is good value based on its PE Ratio (14.2x) compared to the HK Biotechs industry average (38.8x).
PE vs Market: 1061 is poor value based on its PE Ratio (14.2x) compared to the Hong Kong market (11.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1061's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1061 is good value based on its PB Ratio (2.2x) compared to the HK Biotechs industry average (3.4x).
How is Essex Bio-Technology forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1061's forecast earnings growth is above the savings rate (1.5%).
Earnings vs Market: Insufficient data to determine if 1061's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1061's revenue (17.6% per year) is forecast to grow faster than the Hong Kong market (13.4% per year).
High Growth Revenue: 1061's revenue (17.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1061's Return on Equity is forecast to be high in 3 years time (29.6%)
How has Essex Bio-Technology performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1061 has a high level of non-cash earnings.
Growing Profit Margin: 1061's current net profit margins (22.4%) are lower than last year (23.6%).
Past Earnings Growth Analysis
Earnings Trend: 1061's earnings have grown by 17.5% per year over the past 5 years.
Accelerating Growth: 1061's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1061 had negative earnings growth (-27.5%) over the past year, making it difficult to compare to the Biotechs industry average (17.5%).
Return on Equity
High ROE: 1061's Return on Equity (15.4%) is considered low.
How is Essex Bio-Technology's financial position?
Financial Position Analysis
Short Term Liabilities: 1061's short term assets (HK$1.3B) exceed its short term liabilities (HK$606.0M).
Long Term Liabilities: 1061's short term assets (HK$1.3B) exceed its long term liabilities (HK$389.1M).
Debt to Equity History and Analysis
Debt Level: 1061's debt to equity ratio (38.9%) is considered satisfactory.
Reducing Debt: 1061's debt to equity ratio has increased from 12.9% to 38.9% over the past 5 years.
Debt Coverage: 1061's debt is well covered by operating cash flow (53.9%).
Interest Coverage: 1061 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Essex Bio-Technology current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 1061's dividend (0.93%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (1.96%).
High Dividend: 1061's dividend (0.93%) is low compared to the top 25% of dividend payers in the Hong Kong market (5.97%).
Stability and Growth of Payments
Stable Dividend: 1061's dividend payments have been volatile in the past 10 years.
Growing Dividend: 1061's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (13.2%), 1061's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Haizhou Fang (54 yo)
Mr. Haizhou Fang serves as the Managing Director and Executive Director of Essex Bio-Technology Limited and served as its General Manager. Mr. Fang is qualified as a Senior Pharmaceutical Engineer (Profess...
CEO Compensation Analysis
Compensation vs Market: Haizhou's total compensation ($USD225.20K) is about average for companies of similar size in the Hong Kong market ($USD313.12K).
Compensation vs Earnings: Haizhou's compensation has been consistent with company performance over the past year.
Experienced Management: 1061's management team is seasoned and experienced (20.3 years average tenure).
Experienced Board: 1061's board of directors are seasoned and experienced ( 16.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Essex Bio-Technology Limited's company bio, employee growth, exchange listings and data sources
- Name: Essex Bio-Technology Limited
- Ticker: 1061
- Exchange: SEHK
- Founded: 1990
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$3.102b
- Shares outstanding: 576.51m
- Website: https://www.essexbio.com
Number of Employees
- Essex Bio-Technology Limited
- No. 88 Keji 6th Road
- Hi-Tech Zone
- Guangdong Province
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People’s Republic of China and internationally. The company ope...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/11 10:19|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.